Recombinant Human NY-ESO-1 (HLA-A*02:01) Protein (RP02694)

说明书联系我们收藏

Human NY-ESO-1 (HLA-A*02:01) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

The purity of Human NY-ESO-1 (HLA-A*02:01) is greater than 95% as determined by SEC-HPLC.

Immobilized Human NY-ESO-1 (HLA-A*02:01) , His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-NY-ESO-1 (HLA-A*02:01) Antibody, hFc Tag with the EC₅₀ of 12.4ng/ml determined by ELISA.

All(3)|

货号: RP02694

详细信息

种属

Human

表达宿主

HEK293 cells

Calculated MW

50.5 kDa

Observed MW

55-60 kDa

标签

C-His&Avi

纯度

> 95% as determined by Tris-Bis PAGE；> 95% as determined by HPLC

内毒素

Less than 1EU per μg by the LAL method.

描述

Recombinant Human NY-ESO-1 (HLA-A*02:01) Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal.；It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and SLLMWITQV peptide.

储存

Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。

复溶

Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！

客户数据及评论 (0)

折叠内容

背景信息

NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.

Swiss Prot

A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQV

别名

MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1